Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q4 2021 Earnings Presentation

31 slides from Walgreens Boots Alliance's earnings presentation, Oct 14, 2021

  1. Slide 1: Fourth Quarter & Fiscal 2021 Results

    Fiscal 2021 Fourth Quarter & Fiscal 2021 Results October 14, 2021 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1

  2. Slide 2: Safe harbor and non-GAAP

    Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: This presentation and the related discussion contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, any s

  3. Slide 3: WBA Financial Performance

    WBA Financial Performance © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 3

  4. Slide 4: FY21 and 4Q financial highlights

    FY21 and 4Q financial highlights • Strong finish to the year, exceeded expectations • 4Q continuing operations adj. EPS $1.17, +28.1% above prior year in constant Fx • FY21 continuing operations adj. EPS $4.91, +13.7% above prior year in constant Fx ⎯ Includes 34.6 million doses of COVID-19 vaccines

  5. Slide 5: FY21 and 4Q financial highlights

    FY21 and 4Q financial highlights • 4Q results reflected strong execution across the board ⎯ U.S. comparable scripts +8.8%, boosted by COVID-19 vaccines +485bps; 21% share of 4Q vaccinations ⎯ U.S. retail comp sales growth +6.2%, +7.2% excl. tobacco & e. cig ⎯ UK recovery on track and regaining marke

  6. Slide 6: Fiscal year financial highlights

    Fiscal year financial highlights Results Reported Fx Constant Fx FY21 $ in millions (except EPS) B/(W) vs. FY20 B/(W) vs. FY20 Sales (continuing) $132,509 + 8.6% + 7.5% Operating income GAAP $2,342 + 138.4% (continuing) Adjusted $5,117 + 8.2% + 7.7% EPS - total GAAP $2.93 + $2.42 Adjusted $5.31 + 11

  7. Slide 7: 4Q financial highlights

    4Q financial highlights Results Reported Fx Constant Fx 4Q21 $ in millions (except EPS) B/(W) vs. 4Q20 B/(W) vs. 4Q20 Sales (continuing) $34,262 + 12.8% + 11.8% Operating income GAAP $910 + 49.7% (continuing) Adjusted $1,236 + 22.9% + 22.1% EPS - total GAAP $0.72 + 68.0% Adjusted $1.17 + 14.9% + 13.

  8. Slide 8: United States – financials

    United States – financials Continuing operations $ in millions 4Q21 B/(W) vs. 4Q20 FY21 B/(W) vs. FY20 Sales $28,755 + 6.6% $112,005 + 4.0% Adj. gross profit $6,234 + 13.7% $23,759 + 5.5% Adj. SG&A % of sales 17.8% - 1.0%p 17.2% - 0.3%p Adj. operating income $1,230 + 16.4% $5,019 + 5.4% Adj. operati

  9. Slide 9: United States – pharmacy

    United States – pharmacy 4Q 4Q FY21 FY21 4Q21 vs. 4Q20 | FY21 vs. FY20 Total Comparable Total Comparable Pharmacy sales + 6.7% + 8.9% + 5.5% + 6.7% Prescriptions + 8.6% + 8.8% + 3.8% + 5.0% • 4Q comparable scripts grew +8.8% boosted by COVID-19 vaccinations +485bps ⎯ 13.5 million COVID-19 vaccinatio

  10. Slide 10: United States – retail

    United States – retail 4Q FY21 4Q21 vs. 4Q20 | FY21 vs. FY20 Total retail sales + 6.5% - 0.4% Comparable retail sales + 6.2% + 1.2% • 4Q comp. retail sales +6.2%; excluding tobacco +7.2%, improved sequentially with broad based growth across all categories ⎯ Health and wellness +14.0% driven by late

  11. Slide 11: U.S. operational updates – pharmacy

    U.S. operational updates – pharmacy • Continued progress on modernizing pharmacy operating model ⎯ iA Rx automated micro-fulfillment centers currently servicing >800 locations ⎯ On track for nine operational markets by end of FY22 • Village Medical at Walgreens roll-out plans on track ⎯ 52 locations

  12. Slide 12: U.S. operational updates – retail

    U.S. operational updates – retail • Customer Engagement Platform learnings continuously enhancing personalized offerings ⎯ myWalgreens membership +13% vs. 3Q21 to ~85m members to date ⎯ Mass personalization boosted 4Q retail sales comps by ~40bps • Omni-channel offerings accelerating ⎯ Digitally ini

  13. Slide 13: International – financials

    International – financials Continuing operations Constant Fx Constant Fx $ in millions 4Q21 B/(W) vs. 4Q20 FY21 B/(W) vs. FY20 Sales $5,507 + 52.6% $20,505 + 34.1% Adj. gross profit $1,198 + 32.7% $4,327 + 7.3% Adj. SG&A % of sales 19.2% + 5.7%p 18.8% + 6.5%p Adj. operating income $140 + $129 $466 +

  14. Slide 14: Boots UK – financials

    Boots UK – financials 4Q FY21 4Q21 vs. 4Q20 | FY21 vs. FY20 (constant Fx) Pharmacy comp. sales + 11.4% + 5.2% Retail comp. sales + 15.0% + 0.9% • Pharmacy comp. sales +11.4%; driven by pharmacy services • 4Q recovery in retail sales ⎯ Store footfall ~+35% vs. prior year; remains ~-30% below pre-COVI

  15. Slide 15: Boots UK operational updates

    Boots UK operational updates • Continued market share gains in beauty ⎯ Boots #1 beauty destination with market share >40% ⎯ Major marketing campaign underpinned strong market share gains ⎯ 44 new brands launched this fiscal year ⎯ Implemented 100th beauty reinvention store during the quarter • Expa

  16. Slide 16: Cash flow

    Cash flow B/(W) $ in millions FY21 vs. FY20 Operating cash flow $5,555 $70 Cash capital expenditure ($1,379) ($5) Free cash flow $4,176 $65 • FY21 free cash flow grew by +1.6% versus prior year, +12.1% excluding the adverse 4Q impact from the Pharmaceutical Wholesale divestiture • Strong operating p

  17. Slide 17: Endnotes

    Endnotes • Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain inf

  18. Slide 18: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  19. Slide 19: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent

  20. Slide 20: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent

  21. Slide 21: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent

  22. Slide 22: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent

  23. Slide 23: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBe

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 28,755 $ 5,507 $ — $ 34,262 Gros

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Three months ended August 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 26,967 $ 3,403 $ — $ 30,371 Gros

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 112,005 $ 20,505 $ — $ 132,509

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Twelve months ended August 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 107,701 $ 14,281 $ — $ 121,982

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Operating income (loss) for United States includes equity earnings (loss) in AmerisourceBergen. As a result of the two month reporting lag, operating inc

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended August 31, Twelve months ended August 31, 2021 2020 2021 2020 Equity earnings (loss) in Amer

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended August 31, 2021 Three months ended August 31, 2020 Earnings before Earnings before Income tax Income tax inc

  31. Slide 31: Free cash flow

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2021 2020 2021 2020 Net cash provided by operating activities (GAAP) $ 1,245 $

Walgreens Boots Alliance — Q4 2021 Earnings Presentation on 6ix